ArticleCell death & disease2021
circEVI5 acts as a miR-4793-3p sponge to suppress the proliferation of gastric cancer.
Article in Cell death & disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Lymph node metastasis-related circHELQ promotes progression and acts as a nanotherapeutic target in colorectal cancer.Journal of nanobiotechnology · 2026Article
- Circular RNA circEVI5 functions as a miR-433 sponge to promote renal cell carcinoma progression via GBP2-mediated oncogenic signaling.Frontiers in oncology · 2026Article
- miR-4793-3p predicts poor prognosis and regulates ferroptosis and invasiveness of breast cancer via targeting RNF169.World journal of surgical oncology · 2025Article
- The potential of circular RNAs as biomarkers and therapeutic targets for gastric cancer: A comprehensive review.Journal of advanced research · 2025Review
- Circular RNAs in Cell Cycle Regulation of Cancers.International journal of molecular sciences · 2024Review
- Circular RNA DNAH14 molecular mechanism in an experimental model of hepatocellular carcinoma treated with Cobalt chloride to mimic the hypoxia-like response of transcatheter arterial chemoembolization.Scientific reports · 2024Article
- Acting mechanism and clinical significance of hsa_circ_0005927 in the invasion and metastasis of gastric cancer.Journal of Cancer · 2024Article
- Diagnostic predictability of serum miR-4793-3p and miR-1180-3p expression in community-acquired pneumonia.Biomarkers in medicine · 2024Article
- Circ_0071589 contributes to growth, angiogenesis, and metastasis of colorectal cancer through regulating miR-296-5p/EN2 axis.Journal of biochemical and molecular toxicology · 2023Article
- A genome-wide landscape of mRNAs, lncRNAs, circRNAs and miRNAs during intramuscular adipogenesis in cattle.BMC genomics · 2022Article
- The FOXO family of transcription factors: key molecular players in gastric cancer.Journal of molecular medicine (Berlin, Germany) · 2022Review
- Circular RNA and Its Roles in the Occurrence, Development, Diagnosis of Cancer.Frontiers in oncology · 2022Review
- circSOBP Inhibits Bladder Cancer Proliferation and Metastasis by Regulating the miR-200a-3p/PTEN Axis and Participating in the Immune Response.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Circular RNAs (circRNAs) are a novel class of endogenous noncoding RNAs (ncRNAs) with a covalently closed loop structure. Accumulating evidence shows that circRNAs play vital roles in the growth, metastasis, treatment and prognosis of various cancers. However, the detailed functions and underlying mechanisms of circEVI5 (hsa_circ_0013162) in gastric cancer (GC) remain undocumented. In this study, the expression levels and prognostic value of circEVI5 were validated in GC tissue samples by using qRT-PCR. circEVI5 was significantly downregulated in GC tissues and cells, and low circEVI5 expression was correlated with poor prognosis. Next, in vitro CCK-8 assay, EdU incorporation assay, PI staining cell cycle assay, and in vivo xenograft mouse models were conducted to assess the functions of circEVI5. Gain of function experiments indicated that circEVI5 could inhibit GC cell proliferation and retard the cell cycle. Moreover, bioinformatics prediction showed that circEVI5 binds to miR-4793-3p, while FOXO1 may be a target of miR-4793-3p. Pull-down assays, RNA immunoprecipitation (RIP) assays, luciferase assays, and western blot were used to confirm the interactions between circEVI5, miR-4793-3p, and FOXO1. Functional assays demonstrated that circEVI5 suppressed the proliferation of GC by sponging miR-4793-3p and increasing FOXO1 expression levels. In conclusion, our study demonstrated that circEVI5 can bind miR-4793-3p as a ceRNA to eliminate the negative regulation of FOXO1, therefore suppressing GC proliferation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.